Advertisement

Topics

Alectinib potential new standard of care for ALK-positive non-small lung cancer

20:00 EDT 5 Jun 2017 | AAAS

(University of Colorado Anschutz Medical Campus) Results of a 303-patient, multi-national phase III clinical trial known as ALEX published today in the New England Journal of Medicine and presented concurrently at the American Society for Clinical Oncology (ASCO) Annual Meeting 2017 argue for alectinib replacing crizotinib as first-line standard of care in advanced ALK-positive non-small cell lung cancer.

Original Article: Alectinib potential new standard of care for ALK-positive non-small lung cancer

NEXT ARTICLE

More From BioPortfolio on "Alectinib potential new standard of care for ALK-positive non-small lung cancer"

Quick Search
Advertisement
 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...